Top Markets
Coin of the day
Evaxion Biotech A/S Evaxion Biotech A/S

Evaxion Biotech A/S

EVAX
株式のランク #29740
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to... Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
株価
$3.14
最終同期: 2026-08-18
時価総額
$19.83M
変化(1日)
0.32%
変化(1年)
3.29%
DK
取引 Evaxion Biotech A/S (EVAX)

カテゴリー

Evaxion Biotech A/S(EVAX)の配当利回りの履歴
Evaxion Biotech A/S(銘柄コード: EVAX)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Evaxion Biotech A/S(EVAX)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)